Changes of the coagulation and fibrinolysis system in malignancy: Their possible impact on future diagnostic and therapeutic procedures

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 8, 2000, Pages 679-692

  Korte, W ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Cancer; Coagulation; Heparin; Markers; Tissue factor; Urokinase plasminogen activator; Urokinase plasminogen activator receptor

Indexed keywords

ANDROSTANOLONE; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CANCER PROCOAGULANT; FIBRIN; FIBRINOGEN; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; RISTOCETIN; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; UROKINASE RECEPTOR; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER RESEARCH; CANCER RISK; CONTROLLED STUDY; CYTOLOGY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0033829581     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.099     Document Type: Review

References (208)

1. Radioiodinated fibrinogen distribution in cancer patients
2. Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias
3. Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung
4. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
5. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell- derived members of the transforming growth factor beta family
6. Procoagulant activity in cancer cells is dependent on tissue factor expression
7. Monoclonal antibody analysis of purified and cell-associated tissue factor
8. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver
9. Expression of tissue factor correlates with grade of malignancy in human glioma
10. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells
11. Constitutive tissue factor expression of human breast cancer cell line MCF-7 is modulated by growth factors
12. Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas
13. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer
14. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue
15. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues
16. Assessment of monocyte function in breast disease
17. Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients
18. Abnormalities of blood coagulation in patients with cancer Mononuclear cell tissue factor generation
19. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity
20. Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions
21. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X
22. Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells
23. Tissue factor expression in human leukemic cells
24. Tissue factor antigen levels in various biological fluids
25. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: Glycosylation of mutants, activity and physical characterization
26. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation
27. Induction of tissue factor-like activity of human monoblastic leukemia cell line by tumor necrosis factor-alpha
28. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes
29. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: Up-regulation of poly(A) polymerase
30. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
31. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues
32. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity
33. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor- dependent coagulation pathway
34. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor
35. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent
36. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: CDNA cloning of the 33-kDa inhibitor reveals its identity inhibitor-2
37. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI
38. Specific interaction between placental protein 5 and heparin
39. Specific interaction between placental protein 5 and thrombin
40. Placental protein 5 is related to blood coagulation and fibrinolytic systems
41. The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells
42. Detection of placental protein five (PP5) and pregnancy-specific glycoprotein (SP1) in benign and malignant breast disease
43. CDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: Identification as placental protein 5 and tissue factor pathway inhibitor-2
44. Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells
45. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/Matrix-associated serine protease inhibitor
46. Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue
47. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells
48. Cancer procoagulant activity studies using synthetic peptidyl substrates
49. Cancer procoagulant shares similarities with albumin but is distinct by biochemical, immunological and functional measures
50. Le(y) glycolipid acts as a co-factor for tumor procoagulant activity
51. Correlation of prognosis of breast cancer patients and expression of Ley which acts as a cofactor of tumor procoagulant
52. Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation
53. Cellular localization of activated factor X by Xa-specific probes
54. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding
55. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung
56. Hemostatic alterations in cancer patients
57. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
58. The hypercoagulable state in cancer patients: Evidence for impaired thrombin inhibitions
59. Contribution of erythrocytes to thrombin generation in whole blood
60. Beta-thromboglobulin in patients with breast cancer
61. Interaction of human tumor cells with human platelets and the coagulation system
62. Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: Possible role in tumor growth
63. Factor X-dependent, thrombin-generating activities on a neuroblastoma cell and their disappearance upon differentiation
64. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties
65. Proaggregatory and procoagulant properties of three murine mammary gland tumor cell lines with different metastatic capabilities
66. Activated platelets signal chemokine synthesis by human monocytes
67. Variability in platelet procoagulant activity in healthy volunteers
68. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
69. Tumor growth: A putative role for platelets?
70. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients
71. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo
72. Umbilical artery catheterization in newborns. III. Thrombosis - A study of some predisposing factors
73. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
74. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response
75. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer
76. Hemostatic alterations are unrelated to the stage of tumor in untreated malignant melanoma and breast carcinoma
77. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies
78. Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes
79. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer
80. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion
81. A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain
82. Evaluation of some hemostatic parameters in patients with cervical carcinoma
83. Immunoquantitation of factor VIII-related antigen (von Willebrand factor antigen) in prostate cancer
84. Factor VIIIR:Ag plasma levels in patients with cervical and ovarian carcinoma
85. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies
86. Endothelial cell function and thrombosis
87. The effect of radiation therapy on von Willebrand factor in patients with angiosarcoma
88. Increase in plasma thrombomodulin and decrease in plasma von Willebrand factor after regular radiotherapy of patients with cancer
89. Von Willebrand factor in head and neck cancer
90. Thromboembolic diseases: Biochemical mechanisms and new possibilities of biological diagnosis
91. Increased plasma thrombomodulin in cancer patients
92. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients
93. Detection of thrombomodulin in human lung cancer cells
94. A subcloned human esophageal squamous cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin-expressing clone - Thrombomodulin as a possible adhesion molecule of squamous cell carcinoma
95. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma
96. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis
97. Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum
98. Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains
99. Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancer
100. Plasma thrombomodulin level in malignancy varies according to the tumor type
101. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial
102. Blood coagulation and thrombosis in patients with ovarian malignancy
103. Evaluating prethrombotic state in lung cancer using molecular markers
104. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation
105. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells
106. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer
107. Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products
108. Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages
109. Fibrin deposition in primary and metastatic human brain tumours
110. Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease
111. Factor XIII modulates intestinal epithelial wound healing in vitro
112. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin
113. Protein C inhibits endocytosis of thrombin-thrombomodulin complexes in A549 lung cancer cells and human umbilical vein endothelial cells
114. Role of activated protein C in facilitating basement membrane invasion by tumor cells
115. Activated protein C levels in patients with gynecologic tumors
116. Hypercoagulable state in patients with advanced gastrointestinal cancer: Evidence for an acquired resistance to activated protein C
117. Activated protein-C resistance in cancer patients
118. Acquired protein C deficiency following cisplatinum-navelbine administration for locally advanced breast cancer. Case report
119. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy
120. Chemotherapy for breast cancer decreases plasma protein C and protein S
121. Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients
122. Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes
123. Invasion of extracellular matrix by cultured colon cancer cells: Dependence on urokinase receptor display
124. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines
125. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
126. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness
127. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1
128. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
129. Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenase
130. Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro
131. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor
132. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion
133. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase
134. Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells
135. G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells
136. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428
137. Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER
138. Androgen induction of urokinase gene expression in LNCaP cells is dependent on their interaction with the extracellular matrix
139. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
140. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
141. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade
142. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer
143. Immunohistochemical identification of tissue factor in solid tumors
144. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor
145. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system
146. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas
147. Tissue factor expression correlates with histological grade in human pancreatic cancer
148. Preand postsurgery activation of blood coagulation in gastric and large bowel cancers: Diagnostic, therapeutic and prognostic hints
149. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis
150. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon
151. Haemostatic abnormalities in lung cancer: Prognostic implications
152. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer
153. Prognostic impact of an activation of coagulation in lung cancer
154. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status
155. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
156. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients
157. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
158. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue
159. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
160. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients
161. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
162. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer
163. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
164. Urokinase-type plasminogen activator receptor in gastric cancer: Tissue expression and prognostic role
165. Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system
166. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer
167. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA cooperative study #75
168. Heparin and cancer
169. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin
170. Subcutaneous heparin treatment increases survival in small cell lung cancer. ″petites cellules″ group
171. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis
172. Clinical trials with anticoagulant and antiplatelet therapies
173. Heparin-associated thrombocytopenia and thrombosis: Optimal therapy with ancrod
174. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis
175. Pharmacological profiling of recombinant tissue factor pathway inhibitor
176. Activated protein C, concentrate for the treatment of meningococcal endotoxin shock in rabbits
177. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis
178. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial
179. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: Results from a historical cohort study
180. Trial of heparin and cyclophosphamide (NSC-26271) in the treatment of lung cancer
181. Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis
182. The effects of unfractionated heparin on survival in patients with malignancy - A systematic review
183. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
184. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants
185. Osteosarcoma: Improved survival with anticoagulation and amputation
186. Chemotherapy with or without anticoagulation as initial management of patients with operable colorectal cancer: A prospective study with at least 5 years follow-up
187. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the cancer and leukemia group B
188. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration
189. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis
190. Heparin induces apoptosis in human peripheral blood neutrophils
191. A heparan sulfate-containing fraction of bone marrow stroma induces maturation of HL-60 cells in vitro
192. Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors
193. Actions of heparin that may affect the malignant process
194. Clinical trials of antiangiogenic agents
195. Mechanism of heparin action
196. Heparin, monocytes, and procoagulant activity
197. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture
198. Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid)
199. Urokinase combination chemotherapy in small cell lung cancer. A phase II study
200. Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites
201. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy
202. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression
203. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors
204. Antisense inhibition of urokinase in a human osteosarcoma cell line
205. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy
206. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors